← Pipeline|ACH-7772

ACH-7772

Phase 1
Source: Trial-derived·Trials: 1
Modality
Vaccine
MOA
BCL-2i
Target
C5
Pathway
Lipid Met
ETEwing SarcomaCrohn's
Development Pipeline
Preclinical
~Feb 2017
~May 2018
Phase 1
Aug 2018
Nov 2028
Phase 1Current
NCT08194507
858 pts·Crohn's
2018-082028-11·Not yet recruiting
858 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-052.6y awayInterim· Crohn's
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1
Not yet…
Catalysts
Interim
2028-11-05 · 2.6y away
Crohn's
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT08194507Phase 1Crohn'sNot yet recr...858DAS28
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-5501PfizerPhase 1BTKBCL-2i
LLY-9749Eli LillyPhase 3C5FGFRi
LLY-1184Eli LillyNDA/BLAC5CD3xCD20
RHH-1546RochePhase 2/3C5CAR-T CD19
RHH-3592RochePhase 1/2GIP-RBCL-2i
GeliderotideNovartisNDA/BLAIL-17ABCL-2i
TezecilimabTakedaNDA/BLATauBCL-2i
BAY-6035BayerPhase 1C5Anti-Aβ
RimaosocimabAmgenPreclinicalFXIaBCL-2i
ARG-1250ArgenxPhase 2C5GLP-1ag